Skye Bioscience (SKYE)
NASDAQ:SKYE
Total Valuation
Skye Bioscience has a market cap or net worth of $23.30M. The enterprise value is $17.69M.
Market Cap$23.30M
Enterprise Value$17.69M
Share Statistics
Skye Bioscience has 33,378,765 shares outstanding. The number of shares has decreased by -2.65% in one year.
Shares Outstanding33,378,765
Owned by Insiders―
Owned by Institutions―
Financial Efficiency
Skye Bioscience’s return on equity (ROE) is -2.79 and return on invested capital (ROIC) is -286.55%.
Return on Equity (ROE)-2.79
Return on Assets (ROA)-1.98
Return on Invested Capital (ROIC)-286.55%
Return on Capital Employed (ROCE)-2.89
Revenue Per Employee0.00
Profits Per Employee-3.50M
Employee Count16
Asset Turnover0.00
Inventory Turnover0.00
Valuation Ratios
The current PE Ratio of Skye Bioscience is ―. Skye Bioscience’s PEG ratio is -0.00571.
PE Ratio―
PS Ratio0.00
PB Ratio1.48
Price to Fair Value1.48
Price to FCF-0.69
Price to Operating Cash Flow>-0.01
PEG Ratio-0.00571
Income Statement
In the last 12 months, Skye Bioscience had revenue of 0.00 and earned -55.92M in profits. Earnings per share was -1.41.
Revenue0.00
Gross Profit-723.35K
Operating Income-58.16M
Pretax Income-55.92M
Net Income-55.92M
EBITDA-57.44M
Earnings Per Share (EPS)-1.41
Cash Flow
In the last 12 months, operating cash flow was -9.22B and capital expenditures -6.31M, giving a free cash flow of -18.40B billion.
Operating Cash Flow-9.22B
Free Cash Flow-18.40B
Free Cash Flow per Share-551.31
Dividends & Yields
Skye Bioscience pays an annual dividend of ―, resulting in a dividend yield of ―
Dividend Per Share―
Dividend Yield―
Payout RatioN/A
Free Cash Flow Yield―
Earnings Yield―
Stock Price Statistics
Beta2.76
52-Week Price Change-49.78%
50-Day Moving Average0.77
200-Day Moving Average2.08
Relative Strength Index (RSI)51.74
Average Volume (3m)822.93K
Important Dates
Skye Bioscience upcoming earnings date is May 7, 2026, After Close (Confirmed).
Last Earnings DateMar 10, 2026
Next Earnings DateMay 7, 2026
Ex-Dividend Date―
Financial Position
Skye Bioscience as a current ratio of 3.30, with Debt / Equity ratio of 1.37%
Current Ratio3.30
Quick Ratio3.30
Debt to Market Cap<0.01
Net Debt to EBITDA0.10
Interest Coverage Ratio0.00
Taxes
In the past 12 months, Skye Bioscience has paid 5.40K in taxes.
Income Tax5.40K
Effective Tax Rate>-0.01
Enterprise Valuation
Skye Bioscience EV to EBITDA ratio is -0.42, with an EV/FCF ratio of -0.56.
EV to Sales0.00
EV to EBITDA-0.42
EV to Free Cash Flow-0.56
EV to Operating Cash Flow-0.56
Balance Sheet
Skye Bioscience has $25.74M in cash and marketable securities with $273.65K in debt, giving a net cash position of $25.46M billion.
Cash & Marketable Securities$25.74M
Total Debt$273.65K
Net Cash$25.46M
Net Cash Per Share$0.76
Tangible Book Value Per Share$0.50
Margins
Gross margin is 0.00%, with operating margin of 0.00%, and net profit margin of 0.00%.
Gross Margin0.00%
Operating Margin0.00%
Pretax Margin0.00%
Net Profit Margin0.00%
EBITDA Margin0.00%
EBIT Margin0.00%
Analyst Forecast
The average price target for Skye Bioscience is $9.16, which is 11.43% higher than the current price. The consensus rating is Moderate Buy
Price Target$9.16
Price Target Upside1208.57% Upside
Analyst ConsensusModerate Buy
Analyst Count6
Revenue Growth Forecast―
EPS Growth Forecast-53.18%